tRNA-derived RNA Fragments and their Role in Nasal SARS-CoV-2 Infection

新发致病性病毒“严重急性呼吸综合征冠状病毒2型”（SARS-CoV-2）的扩散不仅导致了2019冠状病毒病（COVID-19）大流行，还导致了经济衰退。为了战略性地开发针对SARS-CoV-2的抗病毒疗法，迫切需要集中精力确定宿主对SARS-CoV-2的反应机制。非编码rna （ncRNAs）占人类转录产物的98%，是对抗病毒感染的有希望的治疗靶点。利用ncrna作为有希望的治疗靶点的一个有效例子是miR122抑制剂RG-101单剂量抑制丙型肝炎病毒（HCV）。因此，研究ncRNA对新兴病毒的反应可能为开发有效的治疗干预措施提供一条捷径。我们最近发现，鼻腔拭子样本中受SARS-CoV-2影响最大的小ncRNAs （sncRNAs）属于trna衍生的RNA片段（tRFs），这是一个最近发现的ncRNA家族。我们还发现，SARS-CoV-2诱导的tRF不太可能是降解副产物，而是受到严格调控的分子，鼻气道上皮细胞（AECs）可以重现SARS-CoV-2诱导的tRF。与肝炎病毒和呼吸道合胞病毒（RSV）诱导的tRFs相比，sars - cov -2诱导的tRFs具有以下几个特征。鉴于tRF在其他病毒感染中的新作用，包括我们对其在RSV感染中的原病毒作用的早期观察以及我们验证SARS-CoV-2诱导的tRF在调节病毒RNA合成中起重要作用的初步数据，我们假设SARS-CoV-2诱导的tRF在功能上对SARS-CoV-2感染也很重要。我们将通过1)表征tRF特征，以及2)调查tRF是否影响SARS-CoV-2复制和相关宿主反应来解决这一假设。UTMB是BSL4加尔维斯顿国家实验室（GNL）的所在地，该实验室是我们国家应对新发传染病的主要资源。GNL于2020年1月底获得了首个SARS- CoV-19样本，目前正在开展各方面的研究；基础、动物、临床试验和流行病学。我们正在与共同研究者王田博士合作，他是研究宿主对BSL3 RNA病毒反应的专家。她的实验室已经制定了一项纯化SARS-CoV-2的方案。我们最近一直在共同研究AEC模型，以研究宿主与SARS-CoV-2之间的相互作用。该项目的研究结果不仅将为确定SARS-CoV-2复制和发病机制的相关分子机制提供可能，而且对SARS-CoV-2的潜在疾病生物标志物和治疗策略的开发具有重要指导意义。总之，我们团队的总体目标是为设计新型抗病毒药物提供与ncrna相关的信息。

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an emerging pathogenic virus, has resulted in not only the coronavirus disease 2019 (COVID-19) pandemic, but also economic recession. To strategically develop antiviral therapies against SARS-CoV-2, a focused effort in identifying mechanisms on how the host responds to SARS-CoV-2 is urgently needed. Non-coding RNAs (ncRNAs) contribute to 98% of human transcriptional products and are promising therapeutic targets against viral infections. One effective example for utilizing ncRNAs as promising therapeutic targets is that miR122 inhibitor RG-101 suppresses the hepatitis C virus (HCV) with a single dose. Therefore, studying the ncRNA responses for emerging viruses may provide a shortcut to developing effective therapeutic interventions. We recently discovered that the most impacted small ncRNAs (sncRNAs) by SARS-CoV-2 in nasal swab samples belong to tRNA-derived RNA Fragments (tRFs), a recently discovered ncRNA family. We also found that SARS-CoV-2-induced tRFs are unlikely to be degradation byproducts, but tightly regulated molecules, and nasal airway epithelial cells (AECs) can recapitulate tRF induction by SARS-CoV-2. Compared with tRFs induced by hepatitis viruses and respiratory syncytial virus (RSV), SARS-CoV-2-induced tRFs share several features with them. Given the emerging roles of tRFs in other viral infections, including our early observation on their proviral role in RSV infection and our preliminary data validating a SARS-CoV-2-induced tRF being important in regulating viral RNA synthesis, we hypothesize that SARS-CoV-2-induced tRFs are also functionally important to SARS-CoV-2 infection. We will address the hypothesis by 1) characterizing tRF signatures, and 2) investigating whether tRFs affect SARS-CoV-2 replication and associated host responses. UTMB is the home of the BSL4 Galveston National Laboratory (GNL), a leading resource for our national response to emerging infectious diseases. The GNL obtained the first sample of SARS- CoV-19 at the end of January of 2020, and is currently conducting research on all fronts; basic, animal, clinical trials, and epidemiological. We have an ongoing collaboration with co-investigator Dr. Tian Wang, who is an expert in studying host responses to BSL3 RNA viruses. Her laboratory has established a protocol to purify SARS-CoV-2 for the infection. We recently have been working together on AEC models to study the interaction between host and SARS-CoV-2. The results of this project will not only provide the potential to determine the molecular mechanisms associated with the replication and pathogenesis of SARS-CoV-2, but also are highly instructive for the development of potential disease biomarkers and therapeutic strategies for SARS-CoV-2. In conclusion, the overall goal of our team is to provide ncRNAs-related information for designing novel antiviral drugs.